Dermatitis acneiform adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to June 2026, FDA received 5,968 adverse event reports that record the MedDRA preferred term Dermatitis acneiform. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 413 reports in the 12 months to June 2026 and 406 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,087 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 413 (under 0.1%) record this term. Reports for male patients were 45.9% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 139 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Dermatitis acneiform name as a suspect product, in order of name
Drug	Class	Reports with this term
5 Fu		10
5-fluorouracil		23
5-Fu		28
5-Fu Fluorouracil		12
Abraxane	Microtubule inhibitor	17
Adalimumab	Tumor necrosis factor blocker	23
Ado-trastuzumab emtansine		11
Afatinib	Kinase inhibitor	25
Afinitor	Kinase inhibitor	23
Amivantamab		56
Atezolizumab	Programmed death Receptor-1 blocking antibody	27
Avastin	Vascular endothelial growth factor inhibitor	104
Avmapki Fakzynja Co-Pack		13
Azathioprine	Purine antimetabolite	29
Bevacizumab	Vascular endothelial growth factor inhibitor	153
Braftovi		52
Cabometyx	Kinase inhibitor	54
Calcium folinate	Folate analog	28
Calcium Levofolinate		60
Capecitabine	Nucleoside metabolic inhibitor	78
Carboplatin	Platinum-based drug	153
Cetuximab	Epidermal growth factor receptor antagonist	291
Cisplatin	Platinum-based drug	94
Clindamycin	Lincosamide antibacterial	17
Clobetasol		11
Cobimetinib	Kinase inhibitor	41
Cosentyx	Interleukin-17A antagonist	40
Cotellic	Kinase inhibitor	12
Cyclophosphamide	Alkylating drug	33
Dabrafenib	Kinase inhibitor	39
Dexamethasone	Corticosteroid	31
Docetaxel	Microtubule inhibitor	92
Doxorubicin	Anthracycline topoisomerase inhibitor	16
Doxycycline	Tetracycline-class drug	38
Dupixent	Interleukin-4 receptor alpha antagonist	114
Elplat		13
Enbrel	Tumor necrosis factor blocker	73
Entyvio	Integrin receptor antagonist	10
Erbitux	Epidermal growth factor receptor antagonist	531
Erlotinib	Kinase inhibitor	243
Erlotinib hydrochloride	Kinase inhibitor	41
Everolimus	Kinase inhibitor	11
Femara	Aromatase inhibitor	16
Filgotinib		11
Filgrastim	Leukocyte growth factor	15
Fluorouracil	Nucleoside metabolic inhibitor	500
Folinic Acid		103
Gefitinib	Kinase inhibitor	13
Gemcitabine	Nucleoside metabolic inhibitor	31
Gemcitabine hydrochloride	Nucleoside metabolic inhibitor	34
Gemzar		14
Gilotrif	Kinase inhibitor	121
Golimumab	Tumor necrosis factor blocker	10
Herceptin	HER2/neu receptor antagonist	47
Humira		167
Ibrance	Kinase inhibitor	10
Imbruvica	Kinase inhibitor	32
Inflectra	Tumor necrosis factor blocker	22
Infliximab	Tumor necrosis factor blocker	46
Ipilimumab	CTLA-4-directed blocking antibody	20
Iressa	Kinase inhibitor	60
Irinotecan		189
Irinotecan hcl		55
Irinotecan hydrochloride	Topoisomerase inhibitor	54
Isotretinoin	Retinoid	12
Jakafi	Janus kinase inhibitor	37
Keytruda	Programmed death Receptor-1 blocking antibody	17
Kisqali	Kinase inhibitor	11
Koselugo	Kinase inhibitor	56
Lamictal	Anti-epileptic agent	25
Lansoprazole	Proton pump inhibitor	27
Lapatinib	Kinase inhibitor	15
Lazcluze	Kinase inhibitor	13
Lenvima	Kinase inhibitor	12
Leucovorin		137
Leucovorin calcium	Folate analog	56
Levoleucovorin calcium	Folate analog	39
Malarone	Antimalarial	12
Mekinist	Kinase inhibitor	89
Mektovi		38
Mercaptopurine	Nucleoside metabolic inhibitor	10
Mesalamine	Aminosalicylate	12
Methotrexate	Folate analog metabolic inhibitor	36
Mycophenolate mofetil	Antimetabolite immunosuppressant	20
Necitumumab		39
Nintedanib	Kinase inhibitor	10
Nivolumab	Programmed death Receptor-1 blocking antibody	51
Omeprazole	Proton pump inhibitor	20
Opdivo	Programmed death Receptor-1 blocking antibody	35
Osimertinib	Kinase inhibitor	28
Oxaliplatin	Platinum-based drug	456
Ozanimod		11
Paclitaxel	Microtubule inhibitor	85
Panitumumab	Epidermal growth factor receptor antagonist	489
Pantoprazole	Proton pump inhibitor	23
Pembrolizumab	Programmed death Receptor-1 blocking antibody	17
Pemetrexed	Folate analog metabolic inhibitor	62
Perjeta	HER2/neu receptor antagonist	31
Pertuzumab	HER2/neu receptor antagonist	43
Prednisolone	Corticosteroid	12
Prednisone	Corticosteroid	38
Prolia	RANK ligand inhibitor	10
Rabeprazole	Proton pump inhibitor	21
Radiation Therapy		16
Ramucirumab	Vascular endothelial growth factor receptor 2 antagonist	12
Remicade	Tumor necrosis factor blocker	16
Repatha	PCSK9 inhibitor	13
Revlimid	Thalidomide analog	42
Rinvoq	Janus kinase inhibitor	34
Risankizumab		12
Rituximab	CD20-directed cytolytic antibody	37
Rybrevant		65
Selumetinib	Kinase inhibitor	17
Skyrizi	Interleukin-23 antagonist	12
Spironolactone	Aldosterone antagonist	12
Sprycel	Kinase inhibitor	11
Sulfasalazine	Aminosalicylate	11
Sutent	Kinase inhibitor	11
Tacrolimus	Calcineurin inhibitor immunosuppressant	24
Tafinlar	Kinase inhibitor	29
Tagrisso	Kinase inhibitor	69
Tarceva		334
Taxol		12
Taxotere		20
Tipiracil Hydrochloride Trifluridine		11
Tofacitinib	Janus kinase inhibitor	10
Trametinib	Kinase inhibitor	84
Trastuzumab	HER2/neu receptor antagonist	71
Tykerb	Kinase inhibitor	66
Upadacitinib	Janus kinase inhibitor	18
Ustekinumab	Interleukin-12 antagonist	16
Vectibix	Epidermal growth factor receptor antagonist	556
Vedolizumab	Integrin receptor antagonist	23
Vemurafenib	Kinase inhibitor	45
Vincristine		11
Xeljanz	Janus kinase inhibitor	44
Xeloda	Nucleoside metabolic inhibitor	32
Zelboraf	Kinase inhibitor	30
Zoledronic acid	Bisphosphonate	14

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 45 pharmacologic classes with 10 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Dermatitis acneiform name, in order of name
Class	Reports with this term
Aldosterone antagonist	12
Alkylating drug	48
Aminosalicylate	23
Anthracycline topoisomerase inhibitor	22
Anti-epileptic agent	41
Antimalarial	27
Antimetabolite immunosuppressant	20
Aromatase inhibitor	31
Azole antifungal	11
Bisphosphonate	14
Calcineurin inhibitor immunosuppressant	36
CD20-directed cytolytic antibody	47
Corticosteroid	105
CTLA-4-directed blocking antibody	26
Epidermal growth factor receptor antagonist	1,867
Fluoroquinolone antibacterial	13
Folate analog	123
Folate analog metabolic inhibitor	110
HER2/neu receptor antagonist	192
Integrin receptor antagonist	39
Interleukin-12 antagonist	16
Interleukin-17A antagonist	40
Interleukin-23 antagonist	12
Interleukin-4 receptor alpha antagonist	119
Interleukin-6 receptor antagonist	18
Janus kinase inhibitor	145
Kinase inhibitor	1,408
Leukocyte growth factor	25
Lincosamide antibacterial	19
Microtubule inhibitor	194
Nucleoside analog antiviral	14
Nucleoside metabolic inhibitor	701
PCSK9 inhibitor	13
Platinum-based drug	703
Programmed death Receptor-1 blocking antibody	154
Proton pump inhibitor	104
Purine antimetabolite	29
RANK ligand inhibitor	16
Retinoid	25
Tetracycline-class drug	51
Thalidomide analog	48
Topoisomerase inhibitor	76
Tumor necrosis factor blocker	199
Vascular endothelial growth factor inhibitor	265
Vascular endothelial growth factor receptor 2 antagonist	20

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Dermatitis acneiform, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Dermatitis acneiform
Age	Reports	Share
Under 2	12	0.2%
2 to 11	74	1.2%
12 to 17	120	2%
18 to 44	760	12.7%
45 to 64	1,703	28.5%
65 to 74	1,105	18.5%
75 and over	509	8.5%
Age not given	1,685	28.2%

Sex of the patient in the reports that record Dermatitis acneiform
Sex	Reports	Share
Female	2,537	42.5%
Male	2,739	45.9%
Unknown or not given	692	11.6%

Age and sex are as the report gives them. 43.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Dermatitis acneiform: adverse event reports that record this term. https://reportedreactions.com/reaction/dermatitis-acneiform/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Dermatitis acneiform mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page